indirect
immunofluoresc
assay
euroimmun
ag
luebeck
germani
use
investig
avid
immunoglobulin
g
igg
igm
iga
total
ig
iggam
antibodi
respons
sever
acut
respiratori
syndrom
coronaviru
sar
cov
infect
serial
serum
sampl
eight
patient
collect
first
third
ninth
month
onset
infect
evalu
found
lowavid
igg
antibodi
detect
serum
sampl
collect
first
third
ninth
month
onset
symptom
respect
lowavid
antibodi
iga
igm
subclass
detect
serum
sampl
respect
collect
first
month
onset
infect
howev
iga
antibodi
remain
low
avid
proport
patient
even
late
convalesc
consequ
igg
antibodi
avid
assay
gave
better
discrimin
acutephas
lateconvalescentphas
serum
sampl
igm
iga
iggam
assay
two
patient
sequenti
serum
sampl
also
test
igg
avid
human
cov
strain
parallel
sar
cov
infect
induc
anamnest
igg
antibodi
respons
virus
crossreact
antibodi
remain
high
avid
earli
first
month
postinfect
result
show
assay
detect
lowavid
antibodi
may
use
discrimin
earli
late
antibodi
respons
also
distinguish
anamnest
crossreact
antibodi
respons
primari
specif
respons
may
use
clinic
situat
sever
acut
respiratori
syndrom
sar
caus
sar
coronaviru
sar
cov
newli
emerg
infecti
diseas
caus
major
threat
global
public
health
sar
cov
classifi
group
cov
rapidli
spread
affect
countri
across
five
contin
caus
diseas
patient
death
prompt
determin
public
health
measur
interrupt
spread
humanadapt
sar
cov
howev
precursor
viru
remain
anim
reservoir
bat
small
mammal
civet
cat
within
live
gameanim
market
southern
china
like
amplifi
viru
sourc
interspeci
transmiss
human
possibl
precursor
anim
viru
may
adapt
humantohuman
transmiss
pose
renew
threat
human
health
import
maintain
surveil
reemerg
sar
addit
lesson
sar
outbreak
like
relev
confront
futur
novel
emerg
infecti
diseas
threat
diagnosi
sar
cov
infect
human
depend
upon
detect
viral
rna
use
revers
transcriptionpcr
clinic
specimen
detect
antibodi
respons
blood
seroconvers
indirect
immunofluoresc
iif
neutral
test
regard
gold
standard
diagnosi
sar
cov
infect
howev
previou
studi
show
sar
cov
infect
stimul
anamnest
crossreact
ifantibodi
respons
one
human
cov
patient
prior
antibodi
virus
convers
infect
boost
preexist
titer
antibodi
viru
crossreact
antibodi
sar
cov
antibodi
elicit
possibl
patient
prior
immunolog
memori
sar
cov
possibl
howev
patient
past
immunolog
memori
sar
cov
anim
precursor
sar
cov
subsequ
infect
may
inde
manifest
increas
antibodi
sar
cov
titer
give
rise
diagnost
confus
signific
implic
global
public
antibodi
respons
usual
use
indic
host
immun
respons
pathogen
sometim
subclass
qualiti
antibodi
may
provid
addit
use
inform
exampl
immunoglobulin
igm
antibodi
often
use
indic
recent
infect
howev
sar
igm
antibodi
sar
cov
still
detect
month
postinfect
antibodi
avid
strength
multival
antibodi
bind
multival
antigen
affin
strength
singl
antigenantibodi
bond
lowavid
antibodi
usual
produc
primari
respons
strength
avid
antibodi
increas
time
matur
igg
antibodi
respons
igg
avid
use
differenti
current
past
infect
virus
epsteinbarr
viru
cytomegaloviru
west
nile
viru
studi
describ
avid
antibodi
respons
sar
cov
investig
antibodi
avid
option
serodiagnosi
recent
sar
cov
infect
patient
serum
sampl
eight
sar
patient
five
six
sequenti
serum
sampl
avail
investig
serum
sampl
collect
mainli
first
month
serum
sampl
collect
third
ninth
month
onset
sar
anoth
five
pair
serum
sampl
acut
phase
convalesc
phase
sar
patient
use
optim
urea
concentr
serum
sampl
aliquot
store
use
prepar
covinfect
smear
bni
sar
covinfect
vero
cell
biochip
slide
euroimmun
ag
luebeck
germani
use
studi
field
slide
contain
two
biochip
one
sar
covinfect
cell
second
uninfect
cell
cell
smear
prepar
accord
method
describ
previous
briefli
infect
cell
show
infect
harvest
fix
chill
aceton
min
store
use
antibodi
avid
assay
serum
sampl
test
antibodi
avid
sar
cov
cell
use
iif
test
describ
previous
sequenti
serum
sampl
patient
assay
experi
avoid
interassay
variat
briefli
serial
twofold
dilut
start
antiserum
phosphatebuff
salin
pb
ad
duplic
reaction
field
biochip
slide
euroimmun
ag
luebeck
germani
accord
manufactur
instruct
incub
room
temperatur
min
cell
treat
either
urea
tween
pb
solut
tween
pb
min
cell
wash
tween
pb
min
fluoresceinlabel
antihuman
igg
iga
igm
total
ig
iggam
appropri
ad
min
avid
titrat
test
cell
carri
similarli
except
slide
prepar
inhous
previous
describ
antihuman
igg
fluorescein
isothiocyan
conjug
inova
diagnost
san
diego
ca
use
ifdyestain
cell
examin
magnif
uv
fluoresc
microscop
serum
sampl
titer
antibodi
cov
infect
cell
treat
treat
urea
determin
fourfold
reduct
titer
urea
regard
evid
lowavid
antibodi
patient
low
sar
antibodi
titer
eg
possibl
determin
avid
base
fourfold
reduct
antibodi
titer
optim
urea
concentr
concentr
urea
euroimmun
ag
luebeck
germani
use
test
accord
method
describ
acutephas
week
convalescentphas
month
serum
sampl
anoth
five
sar
patient
determin
optim
concentr
urea
discrimin
highand
lowavid
antibodi
serum
dilut
use
unless
otherwis
specifi
incub
room
temperatur
min
cell
treat
separ
differ
concentr
urea
mix
tween
pb
solut
tween
pb
without
urea
control
min
cell
wash
tween
pb
min
fluoresceinlabel
antihuman
igg
ad
min
ifdyestain
cell
examin
magnif
uv
fluoresc
microscop
posit
reaction
appear
distinct
applegreen
fluoresc
infect
cell
mainli
area
cytoplasm
fineto
coarsegranular
structur
contain
viral
materi
fluoresc
degre
fluoresc
intens
score
follow
fluoresc
score
weak
fluoresc
moder
strong
strong
presenc
lowavid
igg
antibodi
infer
reduct
fluoresc
cell
treat
urea
compar
buffertr
control
cell
given
dilut
reduct
score
intens
taken
indic
presenc
lowavid
antibodi
highest
concentr
urea
demonstr
greatest
discrimin
highand
lowavid
antibodi
serum
dilut
consid
optimum
concentr
urea
use
throughout
studi
slide
read
without
knowledg
content
read
perform
twice
antibodi
avid
sar
cov
determin
acutephas
day
onset
lateconvalescentphas
day
onset
serum
sampl
five
patient
determin
optim
concentr
urea
best
discrimin
acutefrom
lateconvalescentphas
serum
sampl
tabl
found
urea
optim
discrimin
igg
acuteand
convalescentphas
serum
sampl
therefor
urea
use
subsequ
assay
antibodi
avid
studi
lowavid
igg
antibodi
detect
serum
sampl
collect
first
day
onset
symptom
tabl
contrast
one
five
serum
sampl
collect
third
month
postinfect
none
eight
serum
sampl
collect
day
onset
lowavid
igg
antibodi
similarli
lowavid
iga
antibodi
detect
serum
sampl
collect
first
day
ill
two
four
serum
sampl
collect
day
one
four
serum
sampl
collect
day
onset
diseas
contrast
lowavid
antibodi
igm
detect
serum
sampl
month
postinfect
detect
serum
sampl
even
within
first
day
ill
igg
igm
iga
iggam
antibodi
respons
serum
sampl
eight
sar
patient
test
b
titer
durat
sar
cov
antibodi
isotyp
differ
patient
denomin
isotyp
test
avid
may
differ
c
two
sar
patient
detect
lowavid
iggam
antibodi
earlier
lowavid
igg
antibodi
antibodi
avid
sequenti
serum
sampl
one
repres
patient
sar
shown
fig
furthermor
sequenti
serum
sampl
two
patient
also
test
igg
avid
human
cov
two
patient
rise
titer
antibodi
andor
antibodi
remain
high
avid
earli
ill
day
onset
contrast
igg
antibodi
respons
sar
cov
patient
low
avid
earli
postinfect
period
becam
high
day
postinfect
beyond
tabl
studi
eight
patient
sar
found
lowavid
igg
antibodi
sar
cov
serum
sampl
collect
within
month
infect
patient
may
also
anamnest
boost
titer
antibodi
human
cov
eg
anamnest
antibodi
respons
high
avid
even
earli
cours
infect
provid
mean
discrimin
primari
recent
antibodi
respons
anamnest
boost
antibodi
titer
patient
nonsar
cov
infect
prior
immunolog
memori
sar
cov
serolog
respons
sar
cov
possibl
march
guest
http
cviasmorg
assess
whether
strategi
also
would
applic
convers
situat
viz
differenti
anamnest
boost
sar
cov
antibodi
patient
anoth
cov
infect
hypothes
like
true
instanc
person
prior
infect
sar
cov
close
relat
anim
viru
infect
anoth
endem
cov
eg
crossreact
boost
antibodi
respons
person
respons
human
cov
infect
may
well
lead
anamnest
respons
sar
cov
potenti
diagnost
dilemma
major
global
public
health
consequ
thu
antibodi
avid
may
use
investig
patient
rise
titer
antibodi
sar
cov
rather
seroconvers
less
like
due
crossreact
serolog
respons
instanc
addit
attempt
detect
pathogen
rna
revers
transcriptionpcr
test
suggest
antibodi
avid
may
help
clarifi
diagnosi
due
pentamer
structur
igm
antibodi
exhibit
higher
avid
igg
iga
agreement
result
show
even
earli
cours
sar
cov
infect
lowavid
igm
antibodi
detect
serum
sampl
contrast
lowavid
iga
antibodi
sar
cov
persist
found
even
month
iggam
antibodi
reflect
composit
complex
dynam
antibodi
thought
earliest
antibodi
detect
avid
may
remain
low
patient
month
summari
determin
igg
avid
provid
addit
diagnost
certainti
differenti
recent
acquir
previou
infect
sar
cov
human
cov
therefor
first
avail
serum
patient
alreadi
detect
antibodi
sar
cov
rise
titer
antibodi
sar
cov
may
necessarili
confirm
sar
cov
infect
